News | December 13, 2023
Pfizer receives regulatory approvals to complete the acquisition of Seagen
Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution
Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
The updated COVID-19 vaccine is tailored to the Omicron XBB.1.5 sublineage of SARS-CoV-2 and is recommended for individuals 6 months of age and older
Proposed combination enhances Pfizer’s position as a leading company in oncology
Products offered on a not-for-profit basis to the 45 lower-income countries now include the full portfolio for which Pfizer has global rights.
CHMP recommendation based on safety, tolerability, and immunogenicity data from a Phase 2/3 trial of the Omicron BA.1-adapted bivalent vaccine
Submission seeks approval for the treatment of COVID-19 in both vaccinated and unvaccinated individuals at high risk
Pfizer aims to achieve net-zero targets ten years earlier than the expectations of the Net-Zero Standard
105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses
Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
Subscribe To Our Newsletter & Stay Updated
